Mira Dx Licenses Yale Technology for Determining Triple Negative Breast Cancer Risk

Although the company aims to introduce a test based on the technology this year, this time line could be impacted by efforts to determine physician need for the test, according to a Mira Dx official.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.